NeuroSense Therapeutics PEG Ratio

The latest PEG ratio for NRSN is -1.73. That is above the sector sector average of -3.76. Investors often review this figure alongside NeuroSense Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, NRSN currently prints -1.73 for PEG ratio, while the sector average sits near -3.76. That is roughly 53.9% above the sector mean. Large gaps often invite a closer look at NeuroSense Therapeutics's growth, margins, and balance sheet.

A PEG ratio of -1.73 for NeuroSense Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (-3.76) and with NRSN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting NRSN's PEG ratio (-1.73), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.